FDA draft guidance on compounding animal drugs from bulk drug substances: a commentary
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2364-9534
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
FDA draft guidance on compounding animal drugs from bulk drug substances: a commentary ; volume:2 ; number:1 ; day:7 ; month:7 ; year:2016 ; pages:1-3 ; date:12.2016
AAPS open ; 2, Heft 1 (7.7.2016), 1-3, 12.2016
- Urheber
-
Karara, Adel H.
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s41120-016-0007-0
- URN
-
urn:nbn:de:1111-2016071018716
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:52 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Karara, Adel H.
- SpringerLink (Online service)
Ähnliche Objekte (12)
FDA drug approvals: Time Is money!
Investigating drug repositioning opportunities in FDA drug labels through topic modeling
Mining FDA drug labels for medical conditions
The First FDA-Approved Antibody-Drug Conjugate
Classification of anticancer drugs: an update with FDA- and EMA-approved drugs
Do investors value the FDA orphan drug designation?
Repurposing FDA-approved drugs for anti-aging therapies
A systematic analysis of FDA-approved anticancer drugs
Evaluierung von FDA-approved Drugs gegen das Humane Cytomegalievirus
FDA‐approved drugs featuring macrocycles or medium‐sized rings
Study of serious adverse drug reactions using FDA-approved drug labeling and MedDRA
Repurposing von FDA-approved drugs zur Therapie des humanen Cytomegalievirus
FDA drug approvals: Time Is money!
Investigating drug repositioning opportunities in FDA drug labels through topic modeling
Mining FDA drug labels for medical conditions
The First FDA-Approved Antibody-Drug Conjugate
Classification of anticancer drugs: an update with FDA- and EMA-approved drugs
Do investors value the FDA orphan drug designation?
Repurposing FDA-approved drugs for anti-aging therapies
A systematic analysis of FDA-approved anticancer drugs
Evaluierung von FDA-approved Drugs gegen das Humane Cytomegalievirus
FDA‐approved drugs featuring macrocycles or medium‐sized rings
Study of serious adverse drug reactions using FDA-approved drug labeling and MedDRA
Repurposing von FDA-approved drugs zur Therapie des humanen Cytomegalievirus
FDA drug approvals: Time Is money!
Investigating drug repositioning opportunities in FDA drug labels through topic modeling
Mining FDA drug labels for medical conditions
The First FDA-Approved Antibody-Drug Conjugate
Classification of anticancer drugs: an update with FDA- and EMA-approved drugs
Do investors value the FDA orphan drug designation?
Repurposing FDA-approved drugs for anti-aging therapies
A systematic analysis of FDA-approved anticancer drugs
Evaluierung von FDA-approved Drugs gegen das Humane Cytomegalievirus
FDA‐approved drugs featuring macrocycles or medium‐sized rings
Study of serious adverse drug reactions using FDA-approved drug labeling and MedDRA